196 filings
Page 4 of 10
8-K
hd0i0n
8 Feb 22
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
5:13pm
POSASR
ic0uiu94
8 Feb 22
Automatic shelf registration (post-effective amendment)
4:02pm
8-K
7bejmuj qfhmf
24 Jan 22
Regulation FD Disclosure
5:06pm
8-K
vggc9jm0qwe 73
10 Jan 22
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
7:14am
8-K
famavhnp
30 Nov 21
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
8:41am
8-K
xgc77cb
22 Nov 21
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
7:25am
8-K
x5eog9vo
10 Nov 21
Other Events
4:34pm
UPLOAD
flrg a6nfgy75695o0o
9 Nov 21
Letter from SEC
12:00am
8-K
hq8zuar2ff2h f4b9
5 Nov 21
Deciphera Pharmaceuticals Announces Top-line Results from the INTRIGUE Phase 3 Clinical Study
7:10am
8-K
voilusr76j7
2 Nov 21
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
4:07pm
CORRESP
59u530yybnkxrv2 19p4
2 Nov 21
Correspondence with SEC
12:00am
UPLOAD
s7ekvcayg9o rc8p
27 Oct 21
Letter from SEC
12:00am
CORRESP
49mcwj7e
8 Oct 21
Correspondence with SEC
12:00am
8-K/A
syudsb
29 Sep 21
Submission of Matters to a Vote of Security Holders
4:01pm
UPLOAD
8k2qwazjo6ujv8
24 Sep 21
Letter from SEC
12:00am
8-K
tcs hlih05gl
17 Sep 21
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
4:01pm
8-K
ha67fckgn70ioi6
17 Sep 21
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European
7:07am